CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on February 8, 2006
Clinical Journal of the American Society of Nephrology
© 2006 American Society of Nephrology
doi: 10.2215/CJN.02021205
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.02021205v1
1/3/374    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drachenberg, C. B.
Right arrow Articles by Ramos, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drachenberg, C. B.
Right arrow Articles by Ramos, E.


ORIGINAL ARTICLES

Histologic versus Molecular Diagnosis of BK Polyomavirus-Associated Nephropathy: A Shifting Paradigm?

Cinthia B. Drachenberg , John C. Papadimitriou , and Emilio Ramos 1

Departments of Medicine and Pathology, University of Maryland School of Medicine, Baltimore, Maryland


1 To whom correspondence should be addressed. E-mail: eramos{at}medicine.umaryland.edu.


   Abstract

Although discovered in 1970 the BK virus infections had no significant clinical impact until the emergence of BK virus-associated allograft nephropathy (BKPVAN). Escalating clinical challenges required better diagnostic tools and delineation of uniform criteria for diagnosis. In recent years, the widespread use of real-time PCR for measuring viral loads has confirmed that BK viruria and viremia are consistently identified before the development of overt nephritis. The identification of this viruria-viremia-nephritis sequence has provided tools for screening renal transplant patients and the possibility of earlier intervention with improved outcomes. Analysis of current clinical trends indicates that despite the fact that a positive renal biopsy is the "gold standard" for the diagnosis of BKPVAN, clinical interventions often are based on the surrogate markers of the disease rather than on tissue diagnosis. This is conceptually supported by the fact that early BKPVAN is focal and liable to tissue sampling errors. Strong arguments remain, however, in favor of retaining the requirement for tissue evaluation in patients who are suspected of having BKPVAN. BKPVAN selectively affects the graft and is likely to occur in a background of immune and/or nonimmune renal injury. A renal biopsy is necessary to exclude other pathologic processes (e.g., acute rejection) that could coexist with BKPVAN or be the main cause of allograft dysfunction. Evaluation of a renal biopsy for the purpose of staging is important for prognosis and is also of paramount importance for the rational assessment of therapeutic success.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Society of Nephrology.